Do you see any chance that if P3 holistically fails, the drug could still get approved for a more limited clinical approach, like PCV or occult? In footy terms, if P3 doesn’t kick a goal, could we at least get a point instead of being out of bounds on the full? What do you think?
Opthea Q and A, page-41
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.5¢ |
Change
-0.010(1.24%) |
Mkt cap ! $978.7M | |||
| Open | High | Low | Value | Volume |
| 81.0¢ | 81.0¢ | 78.8¢ | $1.042M | 1.308M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1823 | 79.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.0¢ | 22000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |